| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Urinary Retention | |||||
| Prostatic Hyperplasia | |||||
| Benign Prostatic Hypertrophy | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Hyperplasia | |||||
| Hypertrophy | |||||
| 3 | More general conditions related to this trial | ||||
| Genital Diseases, Male | |||||
| Pathologic Processes | |||||
| Pathological Conditions, Anatomical | |||||
| Prostatic Diseases | |||||
| Urination Disorders | |||||
| Urologic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Alfuzosin (SL770499) | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Alfuzosin | |||||
| 6 | More general drug interventions related to this trial | ||||
| Adrenergic Agents | |||||
| Adrenergic alpha-Antagonists | |||||
| Adrenergic Antagonists | |||||
| Antihypertensive Agents | |||||
| Cardiovascular Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Sanofi-Aventis | |||||
|
